Document Detail


Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
MedLine Citation:
PMID:  15811145     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The objective of the study was to investigate the effects of cerivastatin therapy on forearm endothelial dependent acetylcholine (ACH) and independent (nitroprusside) vasodilator responses, blood pressure (BP) responses to intravenous infusions of angiotensin II (AII) and noradrenaline (NA) and on 24-h ambulatory BP recordings in type 2 diabetic men. DESIGN: Eleven type 2 diabetic men aged 59 +/- 9 years with total cholesterol levels of 5.0 +/- 1.26 mmol/l, triglycerides of 2.23 mmol/l and high-density lipoprotein cholesterol levels of 1.24 mmol/l completed a double-blind, randomized, crossover trial comparing 8 weeks of cerivastatin therapy (800 microg of nocte) with placebo. Forearm vascular resistance (FVR) responses to intrabrachial-arterial infusions of ACH (3-24 microg/min), nitroprusside (2-16 microg/min), the nitric oxide(NO) synthase inhibitor l-nitro-mono-methyl arginine (l-nmma) (8 micromol/min), ACH during l-NMMA infusion and BP responses to intravenous infusions of AII (12.5-50 ng/min) and NA (20-400 ng/min) were measured at the end of each treatment period. Twenty-four-hour ambulatory BP recordings were also performed. RESULTS: FVR responses to ACH during l-NMMA infusion were significantly (p = 0.026) greater during cerivastatin than during placebo therapy. In contrast, FVR responses to ACH in the absence of NO synthase inhibition did not differ significantly between cerivastatin and placebo therapies (p = 0.81). FVR increased by 31.4 +/- 57.3% in response to l-NMMA infusion during cerivastatin therapy compared with 6.1 +/- 41.2% during placebo therapy (p = 0.20). FVR responses to nitroprusside did not differ between cerivastatin and placebo therapies (p = 0.28), nor did BP responses to AII (systolic BP, p = 0.99; diastolic BP, p = 0.98) or NA (systolic BP, p = 0.21; diastolic BP, p = 0.48). Mean 24-h BP was similar during cerivastatin (123 +/- 10 or 70 +/- 7 mmHg) and placebo therapies (129 +/- 11 or 74 +/- 7 mmHg) (systolic BP, p = 0.26; diastolic BP, p = 0.41). CONCLUSION: Cerivastatin increases FVR responses to ACH in type 2 diabetic men with mild dyslipidaemia but only following NO synthase inhibition. This may indicate an improvement in endothelium-derived hyperpolarizing factor-mediated responses.
Authors:
D Tran; A Lowy; J B Howes; L G Howes
Related Documents :
6496125 - Circulatory and eeg changes during resuscitation in experiments.
20409865 - Self-measured (blood pressure) arterial stiffness index: a promising new measure of art...
14630885 - The effect of meals at different mealtimes on blood pressure and symptoms in geriatric ...
17396075 - Is it a pheochromocytoma?
8943445 - Quantitative assessment of diastolic filling function: a new doppler echocardiographic ...
22914555 - Albuminuria indicates the pressure-associated injury of juxtamedullary nephrons and cer...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  7     ISSN:  1462-8902     ISO Abbreviation:  Diabetes Obes Metab     Publication Date:  2005 May 
Date Detail:
Created Date:  2005-04-06     Completed Date:  2005-07-18     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  273-81     Citation Subset:  IM    
Affiliation:
Department of Clinical Pharmacology, St. George Hospital, University of New South Wales, Gray St. Kogarah, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcholine / diagnostic use
Aged
Analysis of Variance
Angiotensin II / diagnostic use
Blood Pressure Monitoring, Ambulatory
Cross-Over Studies
Diabetes Mellitus, Type 2 / complications,  drug therapy*,  physiopathology
Double-Blind Method
Endothelium, Vascular / drug effects
Forearm / blood supply
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipidemias / complications,  drug therapy
Hypertension / complications,  drug therapy
Infusions, Intravenous
Male
Middle Aged
Nitric Oxide Synthase / antagonists & inhibitors
Nitroprusside / therapeutic use
Norepinephrine / diagnostic use
Pyridines / therapeutic use*
Vascular Resistance / drug effects*
Vasodilator Agents / diagnostic use
omega-N-Methylarginine / diagnostic use
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyridines; 0/Vasodilator Agents; 0/cerivastatin; 11128-99-7/Angiotensin II; 15078-28-1/Nitroprusside; 17035-90-4/omega-N-Methylarginine; 51-41-2/Norepinephrine; 51-84-3/Acetylcholine; EC 1.14.13.39/Nitric Oxide Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of air displacement plethysmograph and bioelectrical impedance for assessing body composi...
Next Document:  Predictors of glycaemic control in indigent patients presenting with diabetic ketoacidosis.